Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: A randomised trial

Tropical Medicine and International Health

Volumn 18, Issue 1, 2013, Pages 96-100

  Sundar, Shyam ^a   Sinha, Prabat ^b   Jha, T K ^c   Chakravarty, Jaya ^a   Rai, Madhukar ^a   Kumar, Nawin ^b   Pandey, Krishna ^b   Narain, M K ^c   Verma, N ^b   Das, V N R ^b   Das, P ^b   Berman, Jonathan ^d   Arana, Byron ^e  

^a BANARAS HINDU UNIVERSITY   (India)

^b RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

^c Kalazar Research Centre Brahmpura   (India)

^d Fast Track Drugs   (United States)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

12 week treatment; Miltefosine; Post kala azar dermal leishmaniasis; Therapeutic response; Tolerance

Indexed keywords

MILTEFOSINE;

DISEASE TREATMENT; HEALTH RISK; LEISHMANIASIS; ORAL HEALTH; PUBLIC HEALTH;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; FOLLOW UP; HUMAN; INDIAN; INTENTION TO TREAT ANALYSIS; LABORATORY; MULTICENTER STUDY; POST KALA AZAR DERMAL LEISHMANIASIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SKIN LEISHMANIASIS; TREATMENT DURATION; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; PHOSPHORYLCHOLINE; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS; YOUNG ADULT;

INDIA;

NASO HEXACANTHUS;

EID: 84871678273     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12015     Document Type: Article

References (13)

1. Aronson NE, Wortmann GW, Johnson SC et al. (1998) Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clinical Infectious Diseases 27, 1457-1464.
2. Bhattacharya SK, Sinha PK, Sundar S et al. (2007) Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. Journal of Infectious Diseases 196, 591-598.
3. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C et al. (2011) Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. American Journal of Tropical Medicine and Hygiene 84, 255-260.
4. Common Toxicity Criteria 2.0 (1999). http://www.eortc.be/services/doc/ctc/ctcv20_4-30-992.pdf. Accesed on 25 September 2012.
5. Fungizone product description (2012) http://www.rxlist.com/fungizone-drug.htm. Accesed on 3 July 2012.
6. Ganguly S, Das NK, Barbhuiya NN & Chatterjee M (2010) Post-kala-azar dermal leishmaniasis - an overview. International Journal of Dermatology 49, 921-931.
7. Machado PR, Ampuero J, Guimarães LH et al. (2010) Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Neglected Tropical Diseases 4, e912.
8. Ramesh V, Shyammisra R, Saxena U & Mukherjee A (1993) Post-kala-azar dermal leishmaniasis: a clinical and therapeutic study. International Journal of Dermatology 32, 272-275.
9. Ramesh V, Katara K, Verma S & Salotra P (2011) Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis. British Journal of Dermatology 165, 411-414.
10. Soto J, Arana BA, Toledo J et al. (2004) Miltefosine for new world cutaneous leishmaniasis. Clinical Infectious Diseases 38, 1266-1272.
11. Sundar S, Jha TK, Thakur CP et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. New England Journal of Medicine 347, 1739-1746.
12. Thakur CP, Narain S, Kumar N, Hassan SM, Jha DK & Kumar A (1997) Amphotericin B is superior to sodium antimony gluconate in the treatment of post-kala azar dermal leishmaniasis. Annals of Tropical Medicine and Parasitology 91, 611-616.
13. Vélez I, López L, Sánchez X, Mestra L, Rojas C & Rodríguez E (2010) Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 83, 351-356.